In an endeavour to facilitate good patient care, Takeda Pharmaceuticals International AG (Takeda), a global research and development-driven pharmaceutical company, and Hikma Pharmaceuticals LLC (Hikma), a fast growing multinational pharmaceutical group, today announced that they have agreed to a new licensing agreement, giving patients further access to Takeda’s portfolio of products in certain markets within the Middle East and North Africa (MENA) region.
Financial details were not disclosed.
“At Takeda, we put patients at the centre of everything we do. As such, our partnership with Hikma is a testament of our commitment to offer patients world-class cardiovascular and metabolism (CVM) medicines while keeping focus on our core therapeutic areas of oncology and gastroenterology,” said Danilo Cassani, Takeda’s Vice President and Area Head Near East, Middle East & Africa. “This will help better serve the unmet medical needs of patients.”
“Our large sales and marketing teams, with particular expertise in promoting cardiovascular and diabetes treatments, are well positioned to drive strong patient access to Takeda’s products. We are pleased to be building on our long history of partnering with Takeda to bring important medicines to the MENA region. This supports our strategy of working with global partners to strengthen our product portfolio in growing therapeutic areas and our commitment to improving patient access to quality medicines,” said Mazen Darwazah, Vice Chairman and CEO of Hikma MENA and Emerging Markets.
The new agreement builds on a long-standing strategic partnership between Hikma and Takeda. The relationship leverages Hikma’s substantial sales and manufacturing presence in MENA and extensive experience of building brands in the region.
This agreement is effective immediately for all markets.